BioAv Cancer Research Results

BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.
Liver, Liver Cancer: Click to Expand ⟱
Liver Cancer
Scientific Papers found: Click to Expand⟱
5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Apoptosis↑, TumCP↓, EMT↓, Imm↑, ChemoSen↑, BioAv↓, TumCG↓, IL2↑, IL12↑, TNF-α↑, P-gp↓, MDR1↓, QoL↑, Casp↑, DNAdam↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, NOTCH1↓, GSK‐3β↓, TumCCA↑, GSH↓, ROS↑, lipid-P↑, c-Iron↑, GPx4↓, ACSL4↑, Ferroptosis↑, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, Akt↓, PI3K↓, mTOR↓, CXCR4↓, Vim↓, PD-L1↓, eff↑, eff↑, ChemoSen↑, ChemoSen↑, chemoP↑,
2762- BetA,    Targeting Effect of Betulinic Acid Liposome Modified by Hyaluronic Acid on Hepatoma Cells In Vitro
- in-vitro, Liver, HepG2
ROCK1↓, RAS↓, *BioAv↓, BioAv↑,
6230- CUR,    Dual redox effects of 2,6-bis-(4-hydroxyl-3-methoxybenzylidene) cyclohexanone (BHMC) on human liver cancer cells, HepG2 via ROS, glutathione and Nrf2/Keap1 pathway
- in-vitro, Liver, HepG2
chemoP↑, selectivity↑, *BioAv↓, *BioAv↑, ROS↑, ROS↓, ROS↑,
1608- EA,    Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, Lung, A549 - in-vitro, Nor, HUVECs
eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   c-Iron↑, 1,   lipid-P↑, 1,   ROS↓, 1,   ROS↑, 4,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   PDK1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 2,   Cyt‑c↑, 1,   Ferroptosis↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   GSK‐3β↓, 1,   mTOR↓, 1,   mTOR⇅, 1,   NOTCH1↓, 1,   PI3K↓, 1,   PTEN↑, 1,   RAS↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration ⓘ

ROCK1↓, 1,   TSC1↑, 1,   TumCP↓, 2,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   IL12↑, 1,   IL2↑, 1,   Imm↑, 1,   PD-L1↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 3,   Dose∅, 1,   eff↑, 3,   MDR1↓, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

E6↓, 1,   E7↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 2,   QoL↑, 1,  
Total Targets: 55

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 2,   BioEnh↑, 1,   Half-Life∅, 1,  
Total Targets: 4

Scientific Paper Hit Count for: BioAv, bioavailability
1 Astragalus
1 Betulinic acid
1 Curcumin
1 Ellagic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:14  Cells:%  prod#:%  Target#:792  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page